Special Issue

Mechanistic and Prognostic Biomarkers in Liver Diseases

Message from the Guest Editors

During the course of acute or chronic liver disease, hepatocytes may passively release intracellular contents or actively secrete signaling molecules that can be detected in plasma or serum. In addition to traditional cell death biomarkers can reveal mitochondrial dysfunction, apoptosis, oxidative stress, and different stages of inflammation. Importantly, mechanistic biomarkers not only help identify potential therapeutic targets and validate intervention strategies, but they may also offer greater sensitivity than standard clinical endpoints. Some biomarkers have the potential to detect liver injury, fibrosis, or cancer earlier than current measures. Others serve as prognostic tools, helping to predict outcomes such as acute liver failure or the likelihood of requiring a liver transplant.For this Special Issue, we invite original research articles and expert reviews that demonstrate the development, application, and value of mechanistic and prognostic biomarkers across the spectrum of liver diseases—both acute and chronic, and of various etiologies. This is an important and exciting field of research, and we look forward to receiving your high-quality submissions.

Guest Editors

Prof. Dr. Hartmut W. Jaeschke

Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA

Dr. Mitchell R. McGill

Fay W. Boozman College of Public Health, UAMS, Little Rock, AR 72205, USA

Deadline for manuscript submissions

30 November 2025

Livers

MDPI

Livers

an Open Access Journal by MDPI

Impact Factor 2.4
CiteScore 3.2

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Hartmut W. Jaeschke
Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA

Author Benefits

High Visibility:
indexed within ESCI (Web of Science), Scopus, EBSCO, and other databases.

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 27.8 days after submission; acceptance to publication is undertaken in 6.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:
APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.